FDA Grants Priority Review to CC-486 for the Treatment of Acute Myeloid Leukemia

The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news